Inhibrx-INBRX-109 SA CS
A Randomized, Double Blind, Placebo controlled, Phase 2 Study of INBRX 109 as Any line Therapy in Conventional Chondrosarcoma
To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat population as measured by progression free survival assessed by central independent radiology review comparing INBRX-109 and placebo.
DiagnosisPatients with unresectable or metastatic conventional chondrosarcoma.
Unresectable or metastatic conventional chondrosarcoma
Prior lines of therapy allowed except prior DR5 agonists.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
This is a multicenter, randomized, blinded, placebo-controlled study of intravenous INBRX-109 in patients with unresectable or metastatic conventional chondrosarcoma.
Study treatments, INBRX-109 or placebo, will be administered through IV infusions every three weeks.
For more information, visit Clinicaltrials.gov